KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Inventory (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Change in Inventory for 16 consecutive years, with -$18.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory fell 343.09% to -$18.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.6 million, a 103.79% decrease, with the full-year FY2025 number at -$2.6 million, down 103.79% from a year prior.
  • Change in Inventory was -$18.8 million for Q4 2025 at Halozyme Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $40.2 million in Q1 2024 to a low of -$18.8 million in Q4 2025.
  • A 5-year average of $5.1 million and a median of $843500.0 in 2025 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: surged 17717.44% in 2022, then crashed 343.09% in 2025.
  • Halozyme Therapeutics' Change in Inventory stood at -$2.2 million in 2021, then skyrocketed by 232.72% to $2.9 million in 2022, then crashed by 149.88% to -$1.5 million in 2023, then soared by 625.94% to $7.7 million in 2024, then plummeted by 343.09% to -$18.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Change in Inventory are -$18.8 million (Q4 2025), $1.1 million (Q3 2025), and $14.5 million (Q2 2025).